TrialClinIQ | $150,000 | (Apr 29, 2026)
Lighthouse Pharmaceuticals | $12,000,000 | (Apr 29, 2026)
Windmill(US) | $12,000,000 | (Apr 29, 2026)
Certified by Founder
Lodge
E2 - Endovascular Engineering
start up
United States
- Menlo Park, California
- 09/04/2026
- Series C
- $80,000,000
Endovascular Engineering, Inc. ("E2"), is a mission driven, venture-backed company focusing on the development and deployment of groundbreaking clot removal technologies that target venous thromboembolism.
- Industry Medical Equipment Manufacturing
- Website https://endovascularengineering.com/
- LinkedIn https://www.linkedin.com/company/endovascular-engineering/
Related People
Dan RoseFounder
Switzerland -
Lausanne, Vaud
With over 20 years of leadership in medtech, currently serving as CEO of E2 as well as Chairman of the Board at UroMems and Lymphatica Medtech. Brings expertise in company leadership, board administration and strategic growth to advance innovative medical technologies. Passionate about fostering organizational success through collaborative leadership and a mission-driven approach to improve healthcare outcomes. Excels in aligning teams with organizational goals and delivering impactful solutions in rapidly evolving markets.
IC Realtime | $2,000,000 | (Apr 29, 2026)
Golden Child | $37,000,000 | (Apr 29, 2026)
Hypervision Surgical | $22,962,410 | (Apr 29, 2026)
dehaze | $3,746,192 | (Apr 29, 2026)
Clarasight | $11,500,000 | (Apr 29, 2026)
Liquid Instruments | $50,000,000 | (Apr 29, 2026)
TriFetch | $1,900,000 | (Apr 28, 2026)
Linexa | $2,342,840 | (Apr 28, 2026)
HrFlow.ai | $7,000,000 | (Apr 28, 2026)